Roche Holding AG banner

Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 324.9 CHF 4.13% Market Closed
Market Cap: CHf262.9B

EV/S

4.7
Current
24%
More Expensive
vs 3-y average of 3.8

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
4.7
=
Enterprise Value
CHf308.6B
/
Revenue
CHf61.5B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
4.7
=
Enterprise Value
CHf308.6B
/
Revenue
CHf61.5B

Valuation Scenarios

Roche Holding AG is trading above its 3-year average

If EV/S returns to its 3-Year Average (3.8), the stock would be worth CHf262.18 (19% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-51%
Maximum Upside
+6%
Average Downside
19%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 4.7 CHf324.9
0%
3-Year Average 3.8 CHf262.18
-19%
5-Year Average 4 CHf280.84
-14%
Industry Average 4.9 CHf342.99
+6%
Country Average 2.3 CHf160.33
-51%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
CHf308.6B
/
Jan 2026
CHf61.5B
=
4.7
Current
CHf308.6B
/
Dec 2026
CHf63.8B
=
4.8
Forward
CHf308.6B
/
Dec 2027
CHf66.3B
=
4.7
Forward
CHf308.6B
/
Dec 2028
CHf69.4B
=
4.4
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close

Market Distribution

In line with most companies in Switzerland
Percentile
65th
Based on 1 077 companies
65th percentile
4.7
Low
0 — 1.3
Typical Range
1.3 — 5.1
High
5.1 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 1.3
Median 2.3
70th Percentile 5.1
Max 2 449.2

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
416.39 CHF
Undervaluation 22%
Intrinsic Value
Price CHf324.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett